Enalapril

Enalapril is an ACE inhibitor (angiotensin-converting enzyme inhibitor), a medicine taken by mouth. The US label read, for VASOTEC tablets (enalapril maleate), lists three uses: treating high blood pressure, treating symptomatic congestive heart failure (usually together with diuretics and digitalis), and slowing the development of overt heart failure in clinically stable people who have no symptoms but have a reduced left ventricular ejection fraction (35 percent or less). Vasotec is the brand name on the label read.

Also called Vasotec · Enalapril maleate

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 3827; UNII 9O25354EPJ. The label names the substance as enalapril maleate, so UNII 9O25354EPJ is the UNII of the maleate salt and is a broad match. MeSH descriptor D004656 is Enalapril. Class: Angiotensin Converting Enzyme Inhibitor (FDA established pharmacologic class, RxClass). The label read is the Bausch Health US LLC label for VASOTEC (enalapril maleate) tablets, application NDA018998, effective 2026-01-23 in openFDA; Drugs@FDA lists the application's sponsor as BAUSCH. Other enalapril labels, including the Epaned oral solution label, were not read. This page records label indications and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 15 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
15
Phase 3 or 4
13
Recruiting
0
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseCompletedTerminatedUnknown statusAll statuses
Phase 1/20011
Phase 21001
Phase 33126
Phase 45027
All phases91515

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

  • Novartis 9 trials
  • Clinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in Poznań 1 trial
  • Ministry of Health, Sri Lanka 1 trial
  • RECORDATI GROUP 1 trial
  • Shenzhen Ausa Pharmed Co.,Ltd 1 trial

And 2 more.

About this drug

Level
Substance
Mechanism
Not reported

Classification codes

  • UNII 9O25354EPJ

Claims and evidence

Context Patients for whom the US label of enalapril (Vasotec) lists an indication: hypertension, symptomatic congestive heart failure, asymptomatic left ventricular dysfunction with ejection fraction 35 percent or less

Recipient
Recipient not specified
Population
Patients described in the indications section of the label. The label does not state an age range in the passages read.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
Included
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of VASOTEC (enalapril maleate) tablets, in the Bausch Health US LLC version dated 2026-01-23 in openFDA, lists the medicine for the treatment of hypertension; for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis; and, in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction 35 percent or less), to decrease the rate of development of overt heart failure.

    Applies to Recipient not specified Patients for whom the US label of enalapril (Vasotec) lists an indication: hypertension, symptomatic congestive heart failure, asymptomatic left ventricular dysfunction with ejection fraction 35 percent or less

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Supports openFDA drug label record for VASOTEC (enalapril maleate) tablets, Bausch Health US LLC label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 39631f1f-5d19-43c1-b504-bf56d991ed97 (manufacturer Bausch Health US LLC, application NDA018998), returned on 2026-11-09. The label text is dated 2026-01-23 (effective_time). Other openFDA records of enalapril labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], INDICATIONS AND USAGE
      How it applies
      The label sentences that give the indications named in the statement, each quoted in the research quote table.
      Retrieved
      Source effective date
      2026-01-23
      Source state
      Current
      Version fingerprint
      5f863c2bf22396afec6b5c4ca54d79c10d17deea45b25bc7f69704b4ea0109a8
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for VASOTEC (enalapril maleate) tablets, Bausch Health US LLC label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 39631f1f-5d19-43c1-b504-bf56d991ed97 (manufacturer Bausch Health US LLC, application NDA018998), returned on 2026-11-09. The label text is dated 2026-01-23 (effective_time). Other openFDA records of enalapril labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260123.
      Retrieved
      Source effective date
      2026-01-23
      Source state
      Current
      Version fingerprint
      5f863c2bf22396afec6b5c4ca54d79c10d17deea45b25bc7f69704b4ea0109a8
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Background openFDA Drugs@FDA record for application NDA018998 (VASOTEC, sponsor BAUSCH): product and sponsor

      Regulator · U.S. Food and Drug Administration (openFDA, Drugs@FDA) · Edition The openFDA Drugs@FDA record for application NDA018998, returned on 2026-11-09. It lists the sponsor and the products of the application; only the first product listing is quoted.

      Locator
      results[0].products[0].brand_name
      How it applies
      Drugs@FDA product listing for application NDA018998, which confirms the product the label belongs to.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      416a5458130c571132ec7563ce9664a1d19380b14779e933909278478bb7dad2
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short values are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

EPANED

No label from the application holder was found in the openFDA label dataset for application NDA208686. This page does not show another labeler's label in its place.

EPANED KIT

No label from the application holder was found in the openFDA label dataset for application NDA204308. This page does not show another labeler's label in its place.

LEXXEL

No label from the application holder was found in the openFDA label dataset for application NDA020668. This page does not show another labeler's label in its place.

TECZEM

No label from the application holder was found in the openFDA label dataset for application NDA020507. This page does not show another labeler's label in its place.

VASERETIC

No label from the application holder was found in the openFDA label dataset for application NDA019221. This page does not show another labeler's label in its place.

VASOTEC

No label from the application holder was found in the openFDA label dataset for application NDA018998. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA018998 VASOTEC
  2. Approval NDA019221 VASERETIC
  3. Supplemental approval NDA018998 VASOTEC
  4. Supplemental approval NDA018998 VASOTEC
  5. Supplemental approval NDA018998 VASOTEC
  6. Supplemental approval NDA018998 VASOTEC
  7. Supplemental approval NDA019221 VASERETIC
  8. Approval NDA020507 TECZEM
  9. Approval NDA020668 LEXXEL
  10. Supplemental approval NDA018998 VASOTEC
  11. Approval NDA204308 EPANED KIT
  12. Supplemental approval NDA204308 EPANED KIT
  13. Supplemental approval NDA204308 EPANED KIT
  14. Approval NDA208686 EPANED

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 6

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 5 efficacy supplement approvals on record.

    ProductNDA018998

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.

    ProductNDA019221

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA020507

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA020668

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 2 efficacy supplement approvals on record.

    ProductNDA204308

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA208686

Registry trials 14

Record details

Record id
cardio:enalapril
Content hash
b560f1dde21772e71b0f6957bea5d4e40bb8f477be23a6a624d2f814084b34b8